A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: OmalizumabBiological: LigelizumabOther: Placebo
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1072
- Registration Number
- NCT03580369
- Locations
- 🇹🇷
Novartis Investigative Site, Samsun, Turkey
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1078
- Registration Number
- NCT03580356
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Medical Resch of Arizona-Div of Allergy Asthma and Immunology, Scottsdale, Arizona, United States
🇺🇸Atria Clinical Research Asthma and Allergy Institute, Little Rock, Arkansas, United States
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
- Conditions
- CMLLeukemia, Myeloid ChronicHematologic DiseasesChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT03578367
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Georgia Regents University, Augusta, Georgia, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: ianalumab
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT03574545
- Locations
- 🇯🇴
Novartis Investigative Site, Amman, Jordan
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 331
- Registration Number
- NCT03570892
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Chattanooga, Tennessee, United States
🇺🇸Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT03568461
- Locations
- 🇺🇸
UCSF Medical Center ., San Francisco, California, United States
🇺🇸City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr1, Duarte, California, United States
🇺🇸Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
- Conditions
- Multiple Sclerosis
- Interventions
- Combination Product: ofatumumab with AICombination Product: ofatumumab with PRF
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 284
- Registration Number
- NCT03560739
- Locations
- 🇪🇸
Novartis Investigative Site, Castilleja de la cuesta, Sevilla, Spain
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
- Conditions
- Chronic Plaque-type Psoriasis
- Interventions
- Procedure: Skin biopsies
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03553823
- Locations
- 🇩🇪
Novartis Investigative Site, Selters, Germany
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 552
- Registration Number
- NCT03551626
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer (TNBC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer Microsatellite Stable (MSS)Ovarian CancerRenal Cell Carcinoma (RCC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Other: NZV930Other: PDR001Drug: NIR178
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT03549000
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom
🇺🇸University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States